Topic: age-related macular degeneration
A lot has changed for Novartis' wet age-related macular degeneration drug Beovu following a safety communication, an analyst wrote.
Novartis' initial review of Beovu side effects didn't raise any alarms, so the company is standing behind its drug's risk-benefit profile.
Regeneron is facing a growing stable of competitors to blockbuster Eylea, but new data could build the older drug's case in the preventive setting.
Regeneron touts Eylea's multiple indications, established user experience and a newly launched prefilled injector as Novartis' rival Beovu enters.
Biogen is putting down $100 million upfront for copycats to Roche's Lucentis, Regeneron's Eylea and new rights for anti-TNF drugs in China.
Novartis' Beovu will be going up against entrenched rivals with a couple blemishes in its label, analysts wrote.
Novartis has its next big drug approval. The FDA on Tuesday approved wet AMD drug Beovu, which will go up against Regeneron and Roche meds.
Regeneron and Roche are already duking it out in wet age-related macular degeneration with Eylea and Lucentis, respectively, and they may have more company later this year.
Regeneron CEO Len Schleifer netted $26.5 million in pay in 2018, keeping him among the top three highest-earning CEOs in the industry.